Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31412357.
- Also identified by DOI 10.1093/cid/ciz787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Delafloxacin is an option for infections due to methicillin-resistant Staphylococcus aureus. In 2017, 22% of isolates from 7 hospitals in Brooklyn, New York, were nonsusceptible to delafloxacin. Isolates belonging to ST105, a strain associated with healthcare-related infections, predominated. Resistance was also found in ST8, a strain (USA300) associated with community-associated infections.
Medical subject headings
- Community-Acquired Infections
- Methicillin-Resistant Staphylococcus aureus
- Staphylococcal Infections